Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro
F Avcu, AU Ural, T Cetin, O Nevruz - Thrombosis research, 2008 - Elsevier
INTRODUCTION: Proteasome inhibitor bortezomib (PS-341) has been the first proteasome
inhibitor that has entered clinical trials with its antiproliferative and proapoptotic effects in
patients with multiple myeloma. Recent studies indicate that proteasome inhibitors can be
useful in prevention of experimental arterial thrombosis in renovascular hypertensive rat
models. The aim of the present study is to investigate the effect of bortezomib on in vitro
platelet aggregation and adenosine triphosphate (ATP) release of human platelets …
inhibitor that has entered clinical trials with its antiproliferative and proapoptotic effects in
patients with multiple myeloma. Recent studies indicate that proteasome inhibitors can be
useful in prevention of experimental arterial thrombosis in renovascular hypertensive rat
models. The aim of the present study is to investigate the effect of bortezomib on in vitro
platelet aggregation and adenosine triphosphate (ATP) release of human platelets …